Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From Underweight – Here’s Why

Group 1: Upgrade and Valuation - Morgan Stanley upgraded Novo Nordisk A/S (NVO) to Equal Weight from Underweight on March 3, adjusting the price target to $40 from $42, reflecting mid-term growth uncertainty and loss of exclusivity risks on semaglutide [1] - The stock's valuation post the selloff on the REDEFINE-4 data better reflects these uncertainties, and consensus estimates have been rebased [1] Group 2: FDA Approvals - Novo Nordisk A/S announced on February 27 that the US FDA approved three new indications for the once-weekly Sogroya injection (5 mg, 10 mg, or 15 mg) for children aged at least 2.5 years with Idiopathic Short Stature (ISS), short stature born Small for Gestational Age without catch-up growth by age 2, and growth failure associated with Noonan Syndrome [2][3] - This approval marks the first long-acting growth hormone supporting children with these three indications in the United States, providing a once-weekly option that alleviates the burden of daily injections for hormone treatment [3] Group 3: Company Overview - Novo Nordisk A/S is a global healthcare company specializing in diabetes care, developing, discovering, manufacturing, and marketing pharmaceutical products [4] - The company's operations are divided into two segments: biopharmaceuticals and diabetes and obesity care, with the latter covering GLP-1, insulin, and other protein-related products [4]